Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial
CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials.
James Waldron
May 19, 2025 9:25am
Sponsored
Innovative Breakthrough in Cancer Testing Developed in Ohio
May 19, 2025 8:00am
Boehringer’s phase 3 lung data get muted response from analysts
May 19, 2025 9:24am
Sponsored
A Smarter Path to Faster, More Reliable Outsourcing Outcomes
May 19, 2025 8:00am
Fierce Biotech Fundraising Tracker: CellCentric, Stylus & more
May 19, 2025 9:00am
Armata links bacteria-killing virus to responses in phase 2
May 19, 2025 8:41am
More News
Applied's rare disease drug suffers another phase 3 failure
May 19, 2025 7:20am
Apnimed eyes sleep apnea approval after positive ph. 3 results
May 19, 2025 6:00am
FDA clears its first blood test for diagnosing Alzheimer's
May 16, 2025 4:30pm
Neurogene details death in Rett syndrome gene therapy trial
May 16, 2025 3:00pm
